Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02296918 |
Title | ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Acerta Pharma BV |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |